셀리악병 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Celiac Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Vitamins & Minerals, Gluten Degrading Enzymes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

셀리악병 치료 시장 동향

세계의 셀리악병 치료 시장 규모는 2024년에 6억 9,020만 달러에 달했으며, 2025-2030년 CAGR 11.7%로 성장할 것으로 예측됩니다. 가장 중요한 것은 전 세계적으로 셀리악병 진단 사례가 증가하고 있다는 점입니다. 최근 추산에 따르면 미국인 100명 중 약 1명이 셀리악병을 앓고 있지만, 상당수의 사례가 진단되지 않은 채로 남아 있습니다. 이러한 진단 사례의 증가는 인식의 증가와 진단 능력의 향상으로 인해 효과적인 치료 및 진단 방법론에 대한 수요 증가로 직결됩니다. 시장은 이러한 환자 증가로 인해 제약 혁신을 주도하고 전문적인 식이 관리의 필요성을 확대하는 혜택을 누리고 있습니다.

셀리악병 증상과 조기 진단의 중요한 역할에 대한 대중의 지식이 계속 증가함에 따라 개인이 점점 더 적극적으로 의료 상담과 검사를 받고 있으며, 이는 사례 식별 증가에 기여하고 있습니다. 특히, 2023년 비욘드 셀리악의 설문조사에 따르면 미국인의 약 50%만이 셀리악병이나 글루텐 민감성에 대해 알고 있는 것으로 나타나 인식 격차를 해소해야 할 필요성이 커지고 있는 것으로 나타났습니다. 그러나 글루텐 프리 식품 산업이 확대되면서 셀리악병을 관리하는 사람들에게 다양한 식이 옵션이 제공되고 있습니다. 이러한 제품의 가용성은 환자가 식이 제한을 준수하는 데 중요한 역할을 하여 건강 결과를 개선하고 시장 성장에 기여합니다.

현장 검사(POCT)의 발전과 같은 진단 방법의 개선은 조기 발견과 개입을 촉진하여 보다 신속하고 효과적인 치료로 이어졌습니다. 고위험군을 대상으로 한 선별 검사 프로그램을 비롯한 여러 국가의 정부 이니셔티브는 시장 발전을 더욱 촉진하고 있습니다. 이러한 선제적 조치는 진단 건수를 늘리고 환자에게 진단 및 치료 옵션을 적시에 제공함으로써 보다 포괄적이고 선제적인 의료 접근 방식을 촉진합니다. 특히, 여러 국가에서 셀리악병에 대한 인식을 높이고 진단 및 치료에 대한 접근성을 높이기 위한 프로그램을 시행하여 증가하는 건강 문제를 해결하기 위한 노력을 강조하고 있습니다.

새로운 치료 방식에 대한 지속적인 연구는 향후 몇 년간 셀리악병 치료의 새로운 발전을 보장합니다. 항염증제 및 치료 백신의 개발은 치료 옵션을 개선하고 시장 기회를 확대할 것으로 기대됩니다. 또한, 특히 새로운 치료 대안에 대한 의료비 지출 증가와 강력한 R&D 활동이 시장 확대를 주도할 것으로 보입니다. 주요 업체들은 환자 건강을 개선하고 시장 침투를 촉진하며 확대되는 소비자 기반을 충족시키는 데 중점을 두면서 약물 및 글루텐 프리 제품에 점점 더 많은 투자를하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 셀리악병 치료 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 셀리악병 치료 시장 : 치료별 비즈니스 분석

• 치료별 시장 점유율(2024년, 2030년)
• 치료별 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료별(2018-2030년)
• 비타민 및 미네랄
• 글루텐 분해 효소
• 치료(항염증제, 항히스타민제, 기타)
• 기타

제5장 셀리악병 치료 시장 : 유통 채널별 비즈니스 분석

• 유통 채널별 시장 점유율(2024년, 2030년)
• 유통 채널별 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유통 채널별(2018-2030년)
• 병원 약국
• 소매 약국
• 기타

제6장 셀리악병 치료 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일 및 상장 기업
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC.
  • GLENMARK PHARMACEUTICALS LTD.
  • Takeda Pharmaceutical Company Limited
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc.
  • Novartis Pharmaceuticals Corporation
  • BioLineRx

HBR

영문 목차

영문목차

Celiac Disease Treatment Market Trends:

The global celiac disease treatment market size was estimated at USD 690.2 million in 2024 and is projected to grow at a CAGR of 11.7% from 2025 to 2030. Foremost among these is the escalating prevalence of diagnosed celiac disease cases globally. According to recent estimates, approximately 1 in 100 Americans suffers from celiac disease, although a significant proportion of cases remain undiagnosed. This rise in diagnosed instances, attributed to increased awareness and improved diagnostic capabilities, directly translates into a greater demand for effective treatments and diagnostic methodologies. The market benefits from this increasing patient base, driving pharmaceutical innovation and expanding the need for specialized dietary management.

As public knowledge about celiac disease symptoms and the crucial role of early diagnosis continues to grow, individuals are increasingly proactively seeking medical consultations and testing, thereby contributing to the increased identification of cases. Notably, a 2023 survey by Beyond Celiac revealed that only approximately 50% of Americans know anything about celiac disease or gluten sensitivity, indicating a growing awareness gap that needs to be bridged. However, the expanding gluten-free food industry offers a diverse range of dietary options for individuals managing the disease. The availability of these products plays a significant role in patient adherence to dietary restrictions, thereby improving health outcomes and contributing to market growth.

Improvements in detection methods, such as advancements in point-of-care testing (POCT), have facilitated earlier identification and intervention, leading to quicker and more effective treatment. Government initiatives across numerous nations, including screening programs targeting high-risk demographics, further bolster market development. These proactive measures increase the number of diagnosed cases and provide patients with timely access to diagnostics and treatment options, thereby promoting a more comprehensive and proactive healthcare approach. Notably, various countries have implemented programs to raise awareness about celiac disease and enhance access to diagnostics and treatment, underscoring the commitment to addressing this growing health concern.

Ongoing research into new therapeutic modalities assures novel developments in the treatment of celiac disease in the coming years. The development of anti-inflammatory drugs and therapeutic vaccines is expected to enhance treatment options and expand market opportunities. Furthermore, increasing healthcare expenditure and robust R&D activities, particularly in novel treatment alternatives, are poised to drive market expansion. Key players are increasingly investing in drugs and gluten-free products, indicating an emphasis on improving patient health, driving market penetration, and catering to an expanding consumer base.

Global Celiac Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global celiac disease treatment market report based on treatment, distribution channel, and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)
• Vitamins & Minerals
• Gluten Degrading Enzymes
• Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others)
• Other Treatments
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Celiac Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Celiac Disease Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Vitamins & Minerals
  • 4.4.1. Vitamins & Minerals Market, 2018 - 2030 (USD Million)
• 4.5. Gluten Degrading Enzymes
  • 4.5.1. Gluten Degrading Enzymes Market, 2018 - 2030 (USD Million)
• 4.6. Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others)
  • 4.6.1. Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others) Market, 2018 - 2030 (USD Million)
• 4.7. Other Treatments
  • 4.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 5. Celiac Disease Treatment Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 5.6. Other Distribution Channels
  • 5.6.1. Other Distribution Channels Market, 2018 - 2030 (USD Million)

Chapter 6. Celiac Disease Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Celiac Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Celiac Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Celiac Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Celiac Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Celiac Disease Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Celiac Disease Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Teva Pharmaceutical Industries Ltd.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Amgen Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Amneal Pharmaceuticals LLC.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. GLENMARK PHARMACEUTICALS LTD.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Takeda Pharmaceutical Company Limited
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Hikma Pharmaceuticals PLC
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Viatris Inc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Zydus Pharmaceuticals, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Novartis Pharmaceuticals Corporation
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. BioLineRx
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료